Summit Therapeutics plc (SMMT): Price and Financial Metrics
SMMT Price/Volume Stats
| Current price | $24.33 | 52-week high | $24.33 |
| Prev. close | $22.70 | 52-week low | $1.64 |
| Day low | $24.33 | Volume | 461,167 |
| Day high | $24.33 | Avg. volume | 3,247,034 |
| 50-day MA | $11.65 | Dividend yield | N/A |
| 200-day MA | $6.19 | Market Cap | 17.08B |
SMMT Stock Price Chart Interactive Chart >
Summit Therapeutics plc (SMMT) Company Bio
Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.
Latest SMMT News From Around the Web
Below are the latest news stories about SUMMIT THERAPEUTICS INC that investors may wish to consider to help them evaluate SMMT as an investment opportunity.
Insiders hold 82% of Summit Therapeutics Inc. (NASDAQ:SMMT), and they've been buying recentlyKey Insights Insiders appear to have a vested interest in Summit Therapeutics' growth, as seen by their sizeable... |
Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call TranscriptSummit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call. All participants will be able to listen only until the question-and-answer portion of this call. We do not expect any technical difficulties today; however, in the event […] |
Summit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational ProgressCompany's net loss for the nine months ended September 30, 2023, stands at $578.4 million, largely due to in-process research and development expenses |
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023MENLO PARK, Calif., November 07, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter and nine months ended September 30, 2023. |
Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical DevelopmentMENLO PARK, Calif., November 02, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development. |
SMMT Price Returns
| 1-mo | 116.27% |
| 3-mo | 189.99% |
| 6-mo | 426.62% |
| 1-year | 1,194.15% |
| 3-year | 285.58% |
| 5-year | 1,631.67% |
| YTD | 832.18% |
| 2023 | -38.59% |
| 2022 | 57.99% |
| 2021 | -42.77% |
| 2020 | 193.75% |
| 2019 | 39.13% |
Continue Researching SMMT
Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...